Ligand to buy UK biotech Vernaliss for $43 million

Under the terms of the proposed UK scheme of arrangement, Ligand would pay Vernalis shareholders £0.062 per share in cash, valuing Vernalis at approximately £32.8 million or $43 million.

Vernalis announced in March that as part of its then-ongoing strategic review, it had decided to commence a formal sales process. If Ligand’s offer is approved by Vernalis shareholders, the transaction is expected to close in October 2018.

As well as giving Ligang a European base, acquiring Vernalis would provide the company with a portfolio of more than eight fully-funded partnered programmes, including programmes in the respiratory, oncology and CNS sectors.

--------------------------------------------------------------------------------------------------------------------------------------------

Editor's Note:

To apply for becoming a contributor of en-CPhI.cn,

welcome to send your CV and sample works to us,

Email: Julia.Zhang@ubmsinoexpo.com.